| Description | Leronlimab (PRO 140) is a humanized IgG4 anti-CCR5 monoclonal antibody. leronlimumab has both anti-HIV and anti-tumor activity, inhibiting CCR-mediated HIV-1 virus and cancer cell metastasis in mouse tumor models. Leronlimab can be used to study HIV non-alcoholic steatohepatitis (NASH) and breast cancer. |
| In vitro | Leronlimab (1-140 mg/mL) binds to CCR5-positive cells up to 98%[1].Leronlimab (80-1750 μg/mL) inhibits calcium response induced by CCL5, CCL3, and CCL4 in MDA-MB-231 cells[1].Leronlimab (175 and 350 mg/mL) blocks the invasion of MDA-MB-231 cells[1].Leronlimab (10 μg/mL; 72 hours) enhances the cytotoxicity of doxorubicin against MDA-MB-231 cells[1]. |
| In vivo | Leronlimab（2 mg；腹腔注射；每周两次）在小鼠异种移植模型中减少了肺转移[1]。 |
| Synonyms | PRO 140 |
| molecular weight | N/A |
| CAS | 674782-26-4 |
| Storage | store at low temperature | store at -20°C |
| References | 1. Jiao X, et al. Leronlimab, a humanized monoclonal antibody to CCR5, blocks breast cancer cellular metastasis and enhances cell death induced by DNA damaging chemotherapy. Breast Cancer Res. 2021 Jan 23;23(1):11. |